New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...
HealthDay on MSN1d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...
thecardiologyadvisor.com5d
Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...
Endocrinology Advisor3d
Real-World Effectiveness of GLP-1 RA vs DPP4i in Moderate to Severe CKD Explored
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).
pulmonologyadvisor1d
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...
Scouted: ‘Nature’s Ozempic’? Experts Weigh in on the Budding GLP-1 Supplement Boom
Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...
Endocrinology Advisor3d
Select GLP-1 Receptor Agonists Reduce Risk of CKD Progression, ESKD, and MACE
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
pulmonologyadvisor1d
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
Websites that sell compounded GLP-1 RAs often partially inform or misinform consumers, including with respect to US FDA approval.
Renal & Urology News5d
Real-World Effectiveness of GLP-1 RA vs DPP4i in Moderate to Severe CKD Explored
The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i. Real-world data show that treatment with glucagon-like peptide-1 ...
HealthDay on MSN5d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...
EurekAlert!1d
Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among us adults with overweight or obesity
In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...
Medscape3d
Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes
GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...